Zebularine-Resistant Human Cytidine Deaminase Mutants for Optimal Chemoprotection of Hematopoietic Stem Cells

Abstract

Acute myeloid leukemia (AML) is the most common type of acute leukemia. According to the National Cancer Institute, the new cases and deaths from AML in the United States in 2016 are estimated to be approximately 19,990 and 13,400, respectively, with a 5 year survival rate of only about 26.6% (http://seer.cancer.gov/statfacts/html/amyl. html). Thus, there is an urgent need to find more effective ways to improve the clinical treatment of AML.